European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading
BioNTech SE's (NASDAQ:BNTX) Largest Shareholders Are Private Equity Firms With 43% Ownership, Insiders Own 19%
CCORF Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $171
H.C. Wainwright Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $113
Buy Rating Affirmed for BioNTech SE on Strong Phase 2 Results and Positive Valuation
Breakthrough again for tumor mRNA vaccine. Biontech's (BNTX.US) Phase II clinical trial for advanced melanoma is a success.
On July 30th, Biontech (BNTX.US) announced that the Phase II clinical study of BNT111+mRNA vaccine for tumors combined with PD-1 treatment achieved the main endpoint of ORR in unresectable Stage III or IV melanoma patients who progressed after PD-1 treatment.
Jeanel : If analysts are legally responsible for posting false ratings, I don't think anyone would dare to underestimate Tesla![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Lana Su : Tesla is a flag that never falls!
105679891 : ok
OhNowGombie Lana Su : Why don’t you just go buy a dildo?
Ricky Andrade : great